Stock listing

NYSE:ANVS Annovis Bio, Inc. Stock

Home listing (NYSE) of Annovis Bio, Inc.

Follow Annovis Bio, Inc. into a list and get an email when it puts out news.

Share price · NYSE:ANVS

$0.711 USD -0.130 (-15.4%)

Close on Nov 20, 2026

Past year -81.7% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$0.700 – $0.774 USDNov 20, 2026
Volume
1.43M sharesNov 20, 2026
Market cap
$44.12M USDAt the close on Nov 20, 2026 · price × 62.02M shares outstanding
52-week range
$0.620 – $5.500 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$1.75M USDMedian day 850,800 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Annovis Bio, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NYSE:ANVS · Home$0.711 USD-0.130 (-15.4%)1,427,413$0.750$0.774$0.700$0.841Close on Nov 20, 2026
Frankfurt:07X€0.662 EUR-0.086 (-11.5%)—€0.662€0.662€0.662€0.748Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NYSE:ANVS · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.711-0.130-15.4%$0.750$0.774$0.7001,427,413
$0.841+0.098+13.2%$0.768$0.841$0.7431,306,273
$0.743-0.007-0.9%$0.824$0.824$0.7021,884,604
$0.750-0.176-19.0%$0.910$0.920$0.7502,180,078
$0.926+0.079+9.3%$0.885$0.950$0.8182,162,086
$0.847-0.006-0.7%$0.850$0.897$0.8221,163,973
$0.853-0.021-2.4%$0.873$0.873$0.7931,619,169
$0.874-0.027-3.0%$0.900$0.900$0.8111,640,861
$0.901+0.061+7.3%$0.940$0.990$0.8305,192,451
$0.840+0.170+25.4%$0.700$0.850$0.63011,378,100
$0.670-0.540-44.6%$0.880$0.910$0.62030,867,700
$1.210+0.120+11.0%$1.120$1.250$1.1001,433,300
$1.090+0.010+0.9%$1.070$1.150$1.060681,400
$1.080-0.050-4.4%$1.170$1.400$1.0503,010,100
$1.130+0.110+10.8%$1.020$1.170$1.0101,499,400
$1.0200.0000.0%$1.010$1.050$1.0001,482,500
$1.020+0.020+2.0%$0.980$1.030$0.980911,400
$1.000+0.040+4.2%$0.950$1.030$0.950912,800
$0.960-0.040-4.0%$1.000$1.000$0.930593,000
$1.000+0.010+1.0%$0.990$1.010$0.960315,800
$0.9900.0000.0%$0.990$1.050$0.980448,400
$0.990+0.012+1.2%$1.000$1.040$0.990546,300
$0.978+0.018+1.9%$0.960$1.040$0.960703,977
$0.960-0.030-3.0%$0.995$1.040$0.950641,350
$0.990-0.060-5.7%$1.060$1.080$0.990641,400
$1.050+0.030+2.9%$1.040$1.080$1.010572,200
$1.020-0.040-3.8%$1.050$1.080$1.010844,200
$1.060-0.090-7.8%$1.150$1.150$1.050850,800
$1.150-0.060-5.0%$1.210$1.210$1.140460,200
$1.210+0.040+3.4%$1.170$1.240$1.140521,900
$1.170-0.040-3.3%$1.210$1.210$1.140815,400
$1.210+0.030+2.5%$1.170$1.230$1.160429,700
$1.180-0.020-1.7%$1.200$1.240$1.170538,700
$1.200+0.020+1.7%$1.160$1.200$1.140657,600
$1.180+0.010+0.9%$1.190$1.200$1.140648,500
$1.170-0.100-7.9%$1.270$1.280$1.1601,201,800
$1.270-0.030-2.3%$1.300$1.340$1.270572,500
$1.300-0.080-5.8%$1.390$1.410$1.300812,000
$1.380+0.070+5.3%$1.320$1.430$1.3001,190,000
$1.310-0.020-1.5%$1.350$1.360$1.310573,500
$1.330+0.060+4.7%$1.270$1.340$1.230853,900
$1.270+0.010+0.8%$1.300$1.330$1.2401,144,300
$1.260+0.070+5.9%$1.190$1.300$1.1901,214,700
$1.190+0.050+4.4%$1.160$1.220$1.160882,300
$1.140+0.040+3.6%$1.120$1.160$1.090677,900
$1.100+0.060+5.8%$1.100$1.170$1.0801,521,800
$1.040-0.080-7.1%$1.120$1.130$1.0401,431,100
$1.120-0.020-1.8%$1.140$1.140$1.100823,200
$1.140+0.020+1.8%$1.100$1.170$1.1001,201,700
$1.120-0.070-5.9%$1.200$1.230$1.1001,893,400
$1.190-0.030-2.5%$1.210$1.260$1.1701,337,500
$1.220-0.080-6.2%$1.310$1.320$1.2201,743,600
$1.300-0.090-6.5%$1.390$1.400$1.3001,962,800
$1.390+0.010+0.7%$1.400$1.440$1.3801,532,600
$1.380-0.320-18.8%$1.650$1.680$1.3207,332,100
$1.700+0.010+0.6%$1.710$1.760$1.690606,800
$1.690-0.030-1.7%$1.730$1.730$1.670457,200
$1.7200.0000.0%$1.720$1.780$1.700425,500
$1.720-0.090-5.0%$1.780$1.830$1.710498,400
$1.810+0.030+1.7%$1.760$1.810$1.760292,300
$1.780-0.040-2.2%$1.840$1.860$1.760233,600
$1.820+0.070+4.0%$1.760$1.825$1.760560,283
$1.750-0.070-3.8%$1.830$1.830$1.740670,723
$1.820+0.030+1.7%$1.780$1.840$1.770618,600
$1.790-0.060-3.2%$1.840$1.890$1.780548,800
Ticker
NYSE:ANVS
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NYSE
Currency
USD

What changed lately

Latest news

All Annovis Bio, Inc. news

Annovis Bio, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
35 in the last 12 months · 58 in all · newest Nov 20, 2026 · oldest 2025
Decks
11 decks · latest Jan 28, 2026

Where Annovis Bio, Inc. is listed

ListingExchangeCountryCurrency
NYSE:ANVS · Home listing · This pageNYSEUnited StatesUSD
LS Exchange:A2PNH2LS ExchangeGermanyEUR
gettex:07XgettexGermanyEUR
Lang & Schwarz:A2PNH2Lang & SchwarzGermanyEUR
BOATS:ANVSBOATSUnited StatesUSD
Dusseldorf:07XDusseldorfGermanyEUR
Frankfurt:07XFrankfurtGermanyEUR
Munich:07XMunichGermanyEUR
Stuttgart:07XStuttgartGermanyEUR
Tradegate:07XTradegateGermanyEUR

Valuation

Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$41.30M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
No depreciation figure on 6ix yet
Price/book
Negative equity
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
Negative equity
Beta vs S&P 500
2.53

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Annovis Bio, Inc. · NYSE:ANVSUS$44.12MUS$41.30Mn/an/an/an/an/an/a2.53
SunBio, Inc. · KRX:067370US$45.82MUS$42.92M14.2×4.6×8.9×2.0×34.6%0.0×n/a
Apollomics Inc. · NASDAQ:APLMUS$45.28MUS$42.65Mn/a5.0×n/an/a−128.7%n/a1.02
Zelluna ASA · OSL:ZLNAUS$45.02MUS$38.83Mn/an/an/a5.1×n/a0.0×n/a
Oncoinvent ASA · OSL:ONCINUS$44.76MUS$33.80Mn/a14.3×n/a5.4×−673.1%0.0×n/a
Gain Therapeutics, Inc. · NASDAQ:GANXUS$44.50MUS$33.11Mn/an/an/a4.4×n/a0.0×1.60
ImageneBio, Inc. · NASDAQ:IMAUS$44.50M−US$80.79Mn/an/an/a0.3×n/a0.0×0.52
Arch Biopartners, Inc. · TSXV:ARCHUS$44.06MUS$44.06Mn/an/an/an/an/an/a0.94
Spero Therapeutics, Inc. · NASDAQ:SPROUS$43.23M−US$63.10Mn/a−1.5×n/a55.4×−71.0%2.0×1.68
Eloxx Pharmaceuticals, Inc. · NASDAQ:ELOXUS$43.15M−US$1.28Mn/an/an/a1.1×n/a0.3×n/a
Corbus Pharmaceuticals Holdings, Inc. · NASDAQ:CRBPUS$42.45M−US$68.98Mn/an/an/a0.5×n/a0.1×1.85
Median of the othersUS$44.50MUS$33.46M14.2×4.8×8.9×3.2×−99.9%0.0×1.31

Forecasts

3 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 13, 2026. Not 6ix's view and not investment advice.

Price target
10.50 USD · Analysts' mean
EPS, year to Dec 2026
-1.45 · 2 analysts

Team and board

Officers

OfficerRole
Eve DamianoSenior VP, Regulatory Operations
Michael ChristieVP, Process Chemistry
SARAH MacCALLUMVP, Clinical Operations
Cheng FangCSO, Research and Development

Board

DirectorRole
Michael B. HoffmanChairman of the Board
Claudine E. BruckBoard Member
Maria L. MaccecchiniExecutive Board Member
Mark WhiteBoard Member
REID S. McCARTHYBoard Member

Events

QuarterResultsShare move
Q3 2026Nov 13, 2026 · Before open+9.3%
Q2 2026Aug 14, 2026 · Before open+3.4%
Q1 2026May 15, 2026 · Before open−3.3%
Q4 2025Mar 23, 2026−8.8%
Q3 2025Nov 12, 2025 · Before open+15.2%
Q2 2025Aug 12, 2025 · After close−2.5%
Q1 2025May 8, 2025 · After close−4.4%
Q4 2024Mar 21, 2025 · After close+5.7%
Q3 2024Nov 8, 2024 · After close−6.3%
Q2 2024Aug 14, 2024 · After close+14.1%
All 20 quarters
QuarterResultsShare move
Q1 2024May 10, 2024 · After close+15.5%
Q4 2023Mar 29, 2024 · After close+0.5%
Q3 2023Nov 8, 2023 · After close+4.3%
Q2 2023Aug 14, 2023 · After close−2.5%
Q1 2023May 10, 2023 · After close−0.8%
Q4 2022Mar 1, 2023−5.3%
Q3 2022Nov 8, 2022 · After close−3.3%
Q2 2022Aug 8, 2022 · After close+2.6%
Q1 2022May 4, 2022 · After close−3.7%
Q4 2021Mar 2, 2022 · After close−6.6%

Open Events

Decks

DeckKindSlidesDate
Corporate Update (January 2026)Corporate update26 slidesJan 28, 2026
Corporate Update (December 2024)Corporate update23 slidesDec 11, 2024
Corporate Update (June 2024)Corporate update15 slidesJun 11, 2024
Investor Presentation (February 2023)Investor deck28 slidesFeb 13, 2023
Investor Presentation (January 2023)Investor deck27 slidesJan 6, 2023
Corporate Update (October 2021)Corporate update12 slidesOct 5, 2021
AAIC Panel 2021Conference20 slidesJul 29, 2021
IPO Roadshow (May 2021)IPO roadshow25 slidesMay 21, 2021
Investor Presentation (March 2021)Investor deck26 slidesMar 23, 2021
Investor Presentation (June 2020)Investor deck24 slidesJun 9, 2020
All 11 decks
DeckKindSlidesDate
IPO Roadshow (December 2019)IPO roadshow24 slidesDec 10, 2019

Open Decks

Financings

RaiseDate
Public offering of shares of common stock (or pre-funded warrants) and accompanying warrants
Closed: US$21M raised · US$1 a share · Warrants at US$1 for 60 months · Canaccord Genuity
Dealers: Canaccord Genuity (lead)
Buyers: Chairman of the Board ($5.00 million, approximately 24% of the offering)
Insiders: The Chairman of the Board contributed $5.00 million, approximately 24% of the offering
Use of proceeds: Fund operations through the pivotal Phase 3 AD data readout and continued clinical development of buntanetap in AD and PD
Nov 9, 2026
Public offering of underwritten public offering
Closed: US$10M in the latest tranche · US$1.9 a share · Warrants at US$2.5 for 66 months · Canaccord Genuity
Dealers: Canaccord Genuity (lead)
Use of proceeds: Primarily to advance buntanetap through the pivotal Phase 3 Alzheimer's disease trial
Apr 13, 2026
Registered direct offering of shares of common stock
Announced: about US$3.4M · US$2.05 a share · H.C. Wainwright & Co.
Dealers: H.C. Wainwright & Co. (lead)
Buyers: Michael Hoffman; Dr. Maria Maccecchini
Insiders: Participation of Chairman Michael Hoffman and CEO Dr. Maria Maccecchini
Use of proceeds: Working capital and general corporate purposes
Oct 27, 2025
Registered direct offering of shares of common stock (or pre-funded warrants in lieu thereof)
Closed: US$6M raised · US$1.5 a share · H.C. Wainwright & Co.
Dealers: H.C. Wainwright & Co. (lead)
Use of proceeds: Working capital and general corporate purposes
Oct 15, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$6.00 a share on Jan 29, 2020.

Price
US$6.00 a share
Shares offered
2,000,000 shares of common stock
Offering size
US$12 million
Underwriters' option
Up to 300,000 more shares
Listing
ANVS on NYSE American
Underwriter
ThinkEquity
Shares delivered
On or about Jan 31, 2020

Steps

StepWhen
Draft sent to the SEC in confidenceMay 15, 2019
Filed publiclyJul 3, 2019
Amended 6 timesNewest Jan 24, 2020
Shares registered with an exchangeJan 28, 2020
Declared effective by the SECJan 28, 2020
Final prospectus, with the priceJan 30, 2020

Open IPO · From the cover of the final prospectus (424B4) filed Jan 30, 2020

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2012
Revenue000000000185.2K
Cost of revenue11.5K
Gross profit173.7K
Research and development25.2M20.0M38.8M16.5M8.48M3.05M776.3K111.6K273.4K
Selling, general and administrative4.48M6.70M6.24M9.00M6.06M3.59M829.4K602.3K409.1K1.95M
Operating income-29.7M-26.7M-45.0M-25.5M-14.5M-6.64M-1.61M-713.9K-682.4K-1.77M
Depreciation and amortization125.5K14.5M6.64M1.61M713.9K682.4K14.8K
EBITDA-45.0M-25.5M-2210000-1.76M
Interest expense1.85M182.7K13.3K47.2M40.9M66840
Income before tax-28.9M-24.6M-56.2M-25.3M-14.5M-5.46M-991.0K-713.9K-682.3K-1.69M
Income tax0-24.6B-45.0K-182.7K-50.1K-1.21M0-132-682.4K0
Net income-28.9M-24.6M-56.2M-25.3M-14.5M-5.46M-991.0K-713.9K-682.3K-8.32M
Earnings per share, basic-1.40-2.02-6.23-3.10-1.90-0.87-3.51-0.10-0.10
Earnings per share, diluted-1.40-2.31-6.23-3.10-1.90-0.87-3.51

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2012
Cash and equivalents19.5M10.6M5.75M28.4M45.7M8.07M1.86K35.3K347.5K72.3K
Short-term investments10.5B
Receivables735.1K1.47M
Inventory-745.6M22.8K
Current assets21.1M13.9M10.2M36.0M46.0M8.12M747.5K51.0K358.0K1.59M
Property, plant and equipment65.1K
Total assets21.1M13.9M10.2M36.0M46.0M8.12M1.12M51.0K358.0K2.84M
Accounts payable2.59M2.31M1.29M3.96M688.1K341.9K1.23M68.4K71.1K174.4K
Current liabilities3.64M3.88M4.28M7.70M1.51M578.4K2.01M567.9K490.2K174.4K
Long-term debt499.8K
Total debt499.8K
Total liabilities4.23M4.62M18.0M7.70M1.51M578.4K2.62M7.64M7.32M174.4K
Shareholders' equity16.9M9.31M-7.75M28.3M44.5M7.54M-8.58M-7.59M-6.97M2.66M
Shares outstanding27.2M14.1M10.5M8.16M8.10M6.89M282.6K6.82M6.82M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2012
Cash from operations-25.6M-21.9M-40.0M-17.3M-9.13M-3.97M-476.5K-558.6K-537.5K-1.41M
Capital spending0-4-4-40-3000-79.6K
Free cash flow-25.6M-21.9M-40.0M-17.3M-9.13M-3.97M-476.5K-558.6K-537.5K-1.49M
Cash from investing-82.0K
Cash from financing34.6M26.7M17.3M4.61K46.7M12.0M443.1K246.4K332.5K177.7K
Share buybacks46.7M12.0M246.4K332.5K1.29K
Change in cash8.98M4.80M-22.6M-17.3M37.6M8.07M-33.5K-312.2K-205.0K-1.32M

Open Financials

Filings

FilingDateTypeFiled with
10-Q · Quarterly reportNov 13, 2026Quarterly reportSEC
8-K · Current reportNov 13, 2026ResultsSEC
4 · Change in ownershipNov 6, 2026Insider tradeSEC
8-K · Current reportNov 5, 2026Material contractSEC
424B5 · ProspectusNov 5, 2026Offer documentSEC
424B5 · ProspectusNov 4, 2026Offer documentSEC
8-K · Current reportNov 4, 2026ResultsSEC
8-K · Current reportNov 4, 2026Meeting outcomeSEC
8-K · Current reportOct 30, 2026Current reportSEC
8-K · Current reportOct 19, 2026Current reportSEC
Show 200 filings
FilingDateTypeFiled with
SCHEDULE 13G/A · Big-stake notice, amendedOct 15, 2026Big-stake noticeSEC
DEFA14A · Additional proxy materialOct 7, 2026Meeting noticeSEC
DEF 14A · Proxy statementSep 11, 2026Meeting noticeSEC
PRE 14A · Preliminary proxy statementAug 24, 2026Meeting noticeSEC
10-Q · Quarterly reportAug 14, 2026Quarterly reportSEC
8-K · Current reportAug 14, 2026ResultsSEC
SCHEDULE 13G · Big-stake noticeAug 14, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeJul 29, 2026Big-stake noticeSEC
8-K · Current reportJul 9, 2026Current reportSEC
8-K · Current reportJun 17, 2026Meeting outcomeSEC
4 · Change in ownershipMay 21, 2026Insider tradeSEC
8-K · Current reportMay 20, 2026Material contractSEC
424B5 · ProspectusMay 20, 2026Offer documentSEC
424B5 · ProspectusMay 19, 2026Offer documentSEC
10-Q · Quarterly reportMay 15, 2026Quarterly reportSEC
8-K · Current reportMay 15, 2026ResultsSEC
DEFA14A · Additional proxy materialApr 30, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 30, 2026Meeting noticeSEC
8-K · Current reportApr 9, 2026Material contractSEC
424B5 · ProspectusApr 9, 2026Offer documentSEC
4 · Change in ownershipApr 3, 2026Insider tradeSEC
144 · Notice of proposed saleApr 2, 2026Other filingsSEC
8-K · Current reportMar 25, 2026Management or board changeSEC
8-K · Current reportMar 16, 2026ResultsSEC
10-K · Annual reportMar 13, 2026Annual reportSEC
8-K · Current reportFeb 12, 2026Current reportSEC
8-K · Current reportJan 28, 2026Current reportSEC
4 · Change in ownershipDec 8, 2025Insider tradeSEC
4/A · Change in ownership, amendedNov 25, 2025Insider tradeSEC
4 · Change in ownershipNov 25, 2025Insider tradeSEC
4 · Change in ownershipNov 21, 2025Insider tradeSEC
4 · Change in ownershipNov 18, 2025Insider tradeSEC
8-K · Current reportNov 12, 2025ResultsSEC
10-Q · Quarterly reportNov 12, 2025Quarterly reportSEC
4 · Change in ownershipNov 12, 2025Insider tradeSEC
4 · Change in ownershipNov 12, 2025Insider tradeSEC
4 · Change in ownershipNov 12, 2025Insider tradeSEC
8-K · Current reportOct 28, 2025Material contractSEC
424B5 · ProspectusOct 28, 2025Offer documentSEC
8-K · Current reportOct 14, 2025Material contractSEC
424B5 · ProspectusOct 14, 2025Offer documentSEC
UPLOAD · Letter from the SECSep 30, 2025Other filingsSEC
8-K · Current reportSep 29, 2025Management or board changeSEC
CORRESP · Letter to the SECSep 29, 2025Other filingsSEC
CORRESP · Letter to the SECSep 19, 2025Other filingsSEC
UPLOAD · Letter from the SECSep 4, 2025Other filingsSEC
4 · Change in ownershipSep 3, 2025Insider tradeSEC
4 · Change in ownershipAug 20, 2025Insider tradeSEC
8-K · Current reportAug 15, 2025Management or board changeSEC
10-Q · Quarterly reportAug 12, 2025Quarterly reportSEC
8-K · Current reportAug 12, 2025ResultsSEC
8-K · Current reportJun 23, 2025Meeting outcomeSEC
8-K · Current reportJun 20, 2025Current reportSEC
4 · Change in ownershipJun 18, 2025Insider tradeSEC
4 · Change in ownershipJun 16, 2025Insider tradeSEC
4 · Change in ownershipJun 11, 2025Insider tradeSEC
4 · Change in ownershipJun 5, 2025Insider tradeSEC
4 · Change in ownershipJun 2, 2025Insider tradeSEC
3 · Initial statement of ownershipMay 16, 2025Insider tradeSEC
8-K · Current reportMay 13, 2025ResultsSEC
10-Q · Quarterly reportMay 13, 2025Quarterly reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 12, 2025Big-stake noticeSEC
ARS · Annual report to shareholdersMay 1, 2025Annual reportSEC
DEFA14A · Additional proxy materialMay 1, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 30, 2025Meeting noticeSEC
8-K · Current reportMar 27, 2025Management or board changeSEC
10-K · Annual reportMar 21, 2025Annual reportSEC
8-K · Current reportMar 21, 2025ResultsSEC
SCHEDULE 13G · Big-stake noticeFeb 10, 2025Big-stake noticeSEC
8-K · Current reportFeb 5, 2025Current reportSEC
8-K · Current reportFeb 4, 2025Material contractSEC
424B5 · ProspectusFeb 4, 2025Offer documentSEC
424B5 · ProspectusFeb 3, 2025Offer documentSEC
8-K · Current reportDec 11, 2024Current reportSEC
8-K · Current reportDec 11, 2024Material contractSEC
424B5 · ProspectusDec 11, 2024Offer documentSEC
8-K · Current reportDec 9, 2024Management or board changeSEC
8-K · Current reportNov 12, 2024ResultsSEC
10-Q · Quarterly reportNov 8, 2024Quarterly reportSEC
8-K · Current reportOct 15, 2024Current reportSEC
8-K · Current reportSep 30, 2024Current reportSEC
8-K · Current reportAug 15, 2024ResultsSEC
10-Q · Quarterly reportAug 14, 2024Quarterly reportSEC
8-K · Current reportAug 6, 2024Current reportSEC
8-K · Current reportJul 16, 2024Current reportSEC
8-K · Current reportJul 10, 2024Current reportSEC
4 · Change in ownershipJul 3, 2024Insider tradeSEC
4 · Change in ownershipJul 3, 2024Insider tradeSEC
4 · Change in ownershipJul 3, 2024Insider tradeSEC
4 · Change in ownershipJul 3, 2024Insider tradeSEC
4 · Change in ownershipJul 3, 2024Insider tradeSEC
8-K · Current reportJul 2, 2024Current reportSEC
S-8 · Registration statement for employee plansJun 21, 2024Offer documentSEC
8-K · Current reportJun 13, 2024Meeting outcomeSEC
8-K · Current reportJun 11, 2024Current reportSEC
8-K · Current reportJun 5, 2024Current reportSEC
8-K · Current reportMay 21, 2024Current reportSEC
8-K · Current reportMay 13, 2024ResultsSEC
10-Q · Quarterly reportMay 10, 2024Quarterly reportSEC
8-K · Current reportMay 9, 2024Current reportSEC
DEFA14A · Additional proxy materialMay 6, 2024Meeting noticeSEC
8-K · Current reportMay 6, 2024Current reportSEC
8-K · Current reportMay 2, 2024Current reportSEC
8-K · Current reportMay 1, 2024Management or board changeSEC
424B5 · ProspectusMay 1, 2024Offer documentSEC
ARS · Annual report to shareholdersApr 29, 2024Annual reportSEC
DEFA14A · Additional proxy materialApr 29, 2024Meeting noticeSEC
DEF 14A · Proxy statementApr 29, 2024Meeting noticeSEC
8-K · Current reportApr 26, 2024Material contractSEC
8-K · Current reportApr 2, 2024ResultsSEC
10-K · Annual reportMar 29, 2024Annual reportSEC
8-K · Current reportMar 22, 2024Current reportSEC
424B5 · ProspectusMar 21, 2024Offer documentSEC
8-K · Current reportMar 21, 2024Material contractSEC
8-K · Current reportMar 20, 2024Current reportSEC
8-K · Current reportMar 19, 2024Current reportSEC
424B5 · ProspectusMar 18, 2024Offer documentSEC
424B5 · ProspectusMar 18, 2024Offer documentSEC
8-K · Current reportMar 15, 2024Material contractSEC
EFFECT · Notice that a registration is effectiveFeb 13, 2024Other filingsSEC
S-3/A · Registration statement, amendedFeb 12, 2024Offer documentSEC
CORRESP · Letter to the SECFeb 9, 2024Other filingsSEC
UPLOAD · Letter from the SECFeb 5, 2024Other filingsSEC
S-3 · Registration statementFeb 1, 2024Offer documentSEC
SC 13G/A · Big-stake notice, amendedNov 28, 2023Big-stake noticeSEC
4/A · Change in ownership, amendedNov 22, 2023Insider tradeSEC
4/A · Change in ownership, amendedNov 22, 2023Insider tradeSEC
4/A · Change in ownership, amendedNov 22, 2023Insider tradeSEC
4/A · Change in ownership, amendedNov 22, 2023Insider tradeSEC
4/A · Change in ownership, amendedNov 22, 2023Insider tradeSEC
4/A · Change in ownership, amendedNov 22, 2023Insider tradeSEC
4 · Change in ownershipNov 21, 2023Insider tradeSEC
4 · Change in ownershipNov 21, 2023Insider tradeSEC
4 · Change in ownershipNov 21, 2023Insider tradeSEC
4 · Change in ownershipNov 21, 2023Insider tradeSEC
4 · Change in ownershipNov 21, 2023Insider tradeSEC
4 · Change in ownershipNov 21, 2023Insider tradeSEC
10-Q · Quarterly reportNov 8, 2023Quarterly reportSEC
SC 13G · Big-stake noticeNov 8, 2023Big-stake noticeSEC
8-K · Current reportNov 1, 2023ResultsSEC
424B5 · ProspectusNov 1, 2023Offer documentSEC
424B5 · ProspectusOct 30, 2023Offer documentSEC
8-K · Current reportOct 30, 2023Current reportSEC
8-K · Current reportOct 12, 2023Current reportSEC
10-Q · Quarterly reportAug 14, 2023Quarterly reportSEC
8-K · Current reportJun 16, 2023Meeting outcomeSEC
DEFA14A · Additional proxy materialJun 2, 2023Meeting noticeSEC
8-K · Current reportMay 30, 2023Current reportSEC
10-Q · Quarterly reportMay 10, 2023Quarterly reportSEC
ARS · Annual report to shareholdersApr 28, 2023Annual reportSEC
DEF 14A · Proxy statementApr 28, 2023Meeting noticeSEC
4 · Change in ownershipApr 26, 2023Insider tradeSEC
DApr 24, 2023Other filingsSEC
PRE 14A · Preliminary proxy statementApr 17, 2023Meeting noticeSEC
4 · Change in ownershipApr 11, 2023Insider tradeSEC
4 · Change in ownershipApr 11, 2023Insider tradeSEC
4 · Change in ownershipApr 11, 2023Insider tradeSEC
4 · Change in ownershipApr 11, 2023Insider tradeSEC
4 · Change in ownershipApr 11, 2023Insider tradeSEC
4 · Change in ownershipApr 11, 2023Insider tradeSEC
8-K · Current reportApr 4, 2023Current reportSEC
8-K · Current reportApr 3, 2023Material contractSEC
8-K · Current reportApr 3, 2023ResultsSEC
424B5 · ProspectusMar 31, 2023Offer documentSEC
10-K · Annual reportMar 31, 2023Annual reportSEC
8-K · Current reportMar 31, 2023Current reportSEC
8-K · Current reportMar 6, 2023Current reportSEC
8-K · Current reportFeb 13, 2023Current reportSEC
4 · Change in ownershipFeb 8, 2023Insider tradeSEC
4 · Change in ownershipJan 20, 2023Insider tradeSEC
4 · Change in ownershipJan 20, 2023Insider tradeSEC
4 · Change in ownershipJan 20, 2023Insider tradeSEC
4 · Change in ownershipJan 20, 2023Insider tradeSEC
4 · Change in ownershipJan 20, 2023Insider tradeSEC
4 · Change in ownershipJan 20, 2023Insider tradeSEC
8-K · Current reportJan 6, 2023Current reportSEC
10-Q · Quarterly reportNov 8, 2022Quarterly reportSEC
8-K · Current reportSep 12, 2022Management or board changeSEC
4 · Change in ownershipAug 31, 2022Insider tradeSEC
3 · Initial statement of ownershipAug 31, 2022Insider tradeSEC
8-K · Current reportAug 30, 2022Management or board changeSEC
10-Q · Quarterly reportAug 8, 2022Quarterly reportSEC
8-K · Current reportAug 8, 2022ResultsSEC
8-K · Current reportJun 3, 2022Meeting outcomeSEC
10-Q · Quarterly reportMay 4, 2022Quarterly reportSEC
8-K · Current reportMay 4, 2022ResultsSEC
DEFA14A · Additional proxy materialApr 18, 2022Meeting noticeSEC
DEF 14A · Proxy statementApr 18, 2022Meeting noticeSEC
10-K · Annual reportMar 2, 2022Annual reportSEC
4 · Change in ownershipJan 18, 2022Insider tradeSEC

This page holds 200 of 317 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Annovis Bio, Inc.’s releases · as of Nov 13, 2026

Common shares
62,022,520
Fully diluted
62,022,520

Fully diluted

LineSharesAs of
Common shares62,022,520Nov 13, 2026

Warrants and options

Lot
Warrants · US$1.00 · expire about Nov 2031
Warrants · US$2.50 · expire about Oct 2031

Share count over time

CountShares
Nov 13, 202662,022,520
Sep 30, 202642,686,201

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Vanguard1.82M2.9%US$2.31MSep 30, 2026
Marshall Wace, LLP1.7M2.7%US$2.16MSep 30, 2026
Two Sigma748K1.2%US$950KSep 30, 2026
Renaissance Technologies736K1.2%US$935KSep 30, 2026
Geode Capital324K0.52%US$412KSep 30, 2026
BlackRock245K0.40%US$311KSep 30, 2026
Susquehanna243K0.39%US$309KSep 30, 2026
Gsa Capital Partners LLP218K0.35%US$277KSep 30, 2026
Citadel212K0.34%US$269KSep 30, 2026
Morgan Stanley199K0.32%US$253KSep 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
UBS115K0.18%US$146KSep 30, 2026
State Street105K0.17%US$134KSep 30, 2026
Northern Trust68,0700.11%US$86,449Sep 30, 2026
Sherry Group, Inc.57,2700.09%US$72,733Sep 30, 2026
Greenwich Wealth Management LLC56,4000.09%US$71,628Sep 30, 2026
Wescott Financial Advisory Group, LLC41,6070.07%US$52,841Sep 30, 2026
Bridgeway Capital Management, LLC37,1140.06%US$47,135Sep 30, 2026
Empowered Funds, LLC33,0140.05%US$41,928Sep 30, 2026
Dakota Wealth Management29,0000.05%US$36,830Sep 30, 2026
CWA Asset Management Group, LLC28,0000.05%US$35,560Sep 30, 2026
Wells Fargo27,2470.04%US$34,603Sep 30, 2026
StoneX Group Inc.23,9960.04%US$34,716Sep 30, 2026
Sterling Investment Advisors, Ltd.23,4160.04%US$29,738Sep 30, 2026
Nicholson Wealth Management Group, LLC20,0000.03%US$25,400Sep 30, 2026
Wealthspire Advisors, LLC20,0000.03%US$25,400Sep 30, 2026
JPMorgan19,9000.03%US$25,870Sep 30, 2026
Robertson Stephens Wealth Management, LLC18,5790.03%US$23,595Sep 30, 2026
Gill Capital Partners, LLC18,5790.03%US$23,595Sep 30, 2026
R Squared Ltd17,6980.03%US$22,476Sep 30, 2026
Squarepoint Ops LLC16,7690.03%US$21,297Sep 30, 2026
Quadcap Wealth Management, LLC16,1100.03%US$20,460Sep 30, 2026
BNY15,4760.02%US$19,655Sep 30, 2026
Tower Research Capital LLC (TRC)15,2170.02%US$19,326Sep 30, 2026
RKL Wealth Management LLC10,0000.02%US$12,700Sep 30, 2026
Wilmington Savings Fund Society, FSB9,3930.02%US$11,929Sep 30, 2026
Osaic Holdings, Inc.6,6400.01%US$8,433Sep 30, 2026
RBC6,6000.01%US$8,000Sep 30, 2026
Arax Advisory Partners6,5000.01%US$8,255Sep 30, 2026
Gallacher Capital Management LLC5,705<0.01%US$7,245Sep 30, 2026
Covestor Ltd4,863<0.01%US$6,000Sep 30, 2026
PNC Financial Services Group, Inc.2,960<0.01%US$3,759Sep 30, 2026
Pinnacle Financial Group, Inc.2,400<0.01%US$3,048Sep 30, 2026
CoreCap Advisors, LLC2,101<0.01%US$2,668Sep 30, 2026
Nuveen1,861<0.01%US$2,419Sep 30, 2026
SBI Securities Co., Ltd.1,572<0.01%US$1,996Sep 30, 2026
Keating Financial Advisory Services, Inc.1,082<0.01%US$1,374Sep 30, 2026
DiNuzzo Private Wealth, Inc.1,000<0.01%US$1,270Sep 30, 2026
Rockefeller Capital Management L.P.1,000<0.01%US$1,270Sep 30, 2026
Bokf, NA555<0.01%US$705Sep 30, 2026
Steward Partners Investment Advisory, LLC500<0.01%US$635Sep 30, 2026

This page holds 50 of 58 holders. Open Shareholders

Funds

HolderSharesOf the companyValueAs of
Vanguard Total Stock Market Index Fund1.22M2.0%US$2.27MJun 30, 2026
Vanguard Extended Market Index Fund394K0.64%US$733KJun 30, 2026
Fidelity Extended Market Index Fund123K0.20%US$237KMay 31, 2026
iShares Micro-Cap ETF103K0.17%US$192KJun 30, 2026
Fidelity Total Market Index Fund34,4590.06%US$66,161May 31, 2026
Ultra-Small Company Market Fund33,5770.05%US$62,453Jun 30, 2026
Fidelity Series Total Market Index Fund33,4190.05%US$64,164May 31, 2026
Vanguard Balanced Index Fund20,9940.03%US$39,049Jun 30, 2026
Vanguard Institutional Total Stock Market Index Fund12,7230.02%US$23,665Jun 30, 2026
1290 VT Micro Cap Portfolio6,9910.01%US$13,003Jun 30, 2026
All 11 holders
HolderSharesOf the companyValueAs of
Total Stock Market Index Trust557<0.01%US$1,036Jun 30, 2026

Insider trades

TradeTradeSharesPriceValueDate
Hoffman Michael B
Director
Buy5,000,000USD 1.00US$5MNov 6, 2026
Hoffman Michael B
Director
Buy2,562USD 1.75US$4,484May 20, 2026
Hoffman Michael B
Director
Buy18,849USD 1.80US$33,928May 20, 2026
Hoffman Michael B
Director
Buy54,933USD 1.90US$104KMay 20, 2026
Hoffman Michael B
Director
Buy713,800USD 2.10US$1.5MApr 2, 2026

Big stakes

StakeStakeSharesDateFiling
Highbridge Capital Management LLC6.10%2.78MJun 30, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Robert M Whelan Jr
Other companies: iAnthus Capital Holdings, Inc. (Director · Feb 5, 2021 – Feb 5, 2021 · Past); Aspen Technology Inc (Director · May 4, 2011 – Mar 11, 2025 · Past); Ariad Pharmaceuticals Inc (Director · Apr 12, 2010 – Jan 31, 2014 · Past)
Director · Jan 28, 2020 – Jul 1, 2020 · Past
Cheng FangCSO, Research and Development · Since at least Oct 22, 2026
Claudine E. BruckDirector · Since at least Jul 7, 2021
Eve DamianoSenior VP, Regulatory Operations · Since at least Sep 24, 2026
Maria L. MaccecchiniExecutive Board Member · Since at least Oct 29, 2026
Mark WhiteBoard Member · Since at least Nov 17, 2023
Michael B. HoffmanDirector · Since at least Apr 2, 2026
Michael ChristieVP, Process Chemistry · Since at least Nov 4, 2026
REID S. McCARTHYDirector · Since at least Jun 10, 2025
SARAH MacCALLUMVP, Clinical Operations · Since at least Jul 7, 2026

Open People

Log in to ask 6ix AI your own questions about Annovis Bio, Inc.